Clinical Trial Update: Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial of ARO-APOC3 (Plozasiran) in adults with Familial Chylomicronemia Syndrome has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Chylomicronemia Syndrome

Drugs mentioned

• ARO-APOC3 (Plozasiran) (ploza­siran)

Snippet

Sponsor: Arrowhead Pharmaceuticals | Conditions: Familial Chylomicronemia | Phase 3 | Status: COMPLETED | Results posted: 2026-02-04